mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms

Eitemau Tebyg

• Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
  gan: Bartalucci, Niccolò, et al.
  Cyhoeddwyd: (2013)
• Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
  gan: Vannucchi, Alessandro M, et al.
  Cyhoeddwyd: (2009)
• Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis
  gan: Bartalucci, Niccolò, et al.
  Cyhoeddwyd: (2017)
• JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment
  gan: Vannucchi, Alessandro M., et al.
  Cyhoeddwyd: (2011)
• The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera
  gan: Pieri, Lisa, et al.
  Cyhoeddwyd: (2009)